Notice of results

RNS Number : 1224Y

IXICO plc

11 May 2021

 

IXICO plc

("IXICO" or the "Company")

Notice of results

Investor presentation

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience , confirms it will announce its half-year results for the six months ended 31 March 2021 on Tuesday 25 May 2021.

Investor briefing

IXICO will be hosting a live online presentation open to all investors on Tuesday 25 May at 3.30pm (BST). The presentation will be delivered by Giulio Cerroni, Chief Executive Officer, Grant Nash, Chief Financial Officer and Robin Wolz, Chief Scientific Officer.

The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business. The presentation will be hosted through the digital platform Investor Meet Company.

Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link: https://www.investormeetcompany.com/ixico-plc/register-investor

Investors who already follow IXICO plc on the Investor Meet Company platform will automatically be invited.

For further information please contact:

IXICO plc			[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	[phone]
Paul McManus / Lianne Cawthorne /		[e-mail]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com   and follow us on Twitter @IxicoNews  

 

END

 

 

NORGPURGAUPGGWU